Diabetes-Related Vascular and Wound Care Products FDA Approved Medical Products Drugs PLAVIX Plavix is a P2Y12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate
European Association for the Study of Diabetes (EASD) The mission of EASD is to promote excellence in diabetes care through research and education The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. To know more about EASD, click here. 2013 EASD Meeting 49TH ANNUAL
EU EMA CHMP Investigation into GLP-1 based diabetes therapies concluded: No New Concerns JUL-27-2013 No new concerns for GLP-1 therapies identified on the basis of available evidence The European Medicines Agency’s Committee for Medicinal Products for Human Use(CHMP) has finalised a review of GLP-1-based diabetes therapies. The Committee concluded that presently available data do not confirm recent concerns over an increased
From the monster’s mouth: has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? By Dr. David Lim, Ph.D., RAC, ASQ-CQA (LinkedIn) Incretin mimetics have been called “the darlings of diabetes treatment” and they may soon also be licensed for treating obesity. But a BMJ investigation has found growing safety concerns linked to the drugs’ mechanism of action. Deborah Cohen
